Pionyr Immunotherapeutics is in the process of advancing cancer immunotherapies in the clinical stage, specifically targeting the microenvironment of tumors to bolster the body's natural immune response against cancer. The company's Myeloid Tuning™ method aims to modify the myeloid infiltrate within the tumor microenvironment with a high level of precision, with the specific goal of augmenting the immune system's anti-tumor reaction. Pionyr's innovative Myeloid Tuning™ technology is grounded in the revelation that reshaping the tumor microenvironment can promote immune-activating cells over immune-suppressing cells.
Pionyr Immunotherapeutics
Headquarters
United States of America